Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–99.

Article  PubMed  Google Scholar 

Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–15.

Article  PubMed  Google Scholar 

Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304–20.

Article  CAS  PubMed  Google Scholar 

Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respir Rev. 2013;22(127):6–19.

Article  PubMed  PubMed Central  Google Scholar 

Vonk MC, Smith V, Sfikakis PP, Cutolo M, del Galdo F, Seibold JR. Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence. Autoimmun Rev. 2021;20(12): 102978.

Article  CAS  PubMed  Google Scholar 

Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. NEJM. 2019;380(26):2518–28.

Article  CAS  PubMed  Google Scholar 

Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med. 2021;9(1):96–106.

Article  CAS  PubMed  Google Scholar 

Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963–74.

Article  CAS  PubMed  Google Scholar 

Hoffmann-Vold A-M, Allanore Y, Alves M, Brunborg C, Airó P, Ananieva LP, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021;80(2):219–27.

Article  CAS  PubMed  Google Scholar 

Goh NSL, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial Lung Disease in Systemic Sclerosis. Am J Respir Crit Care Med. 2008;177(11):1248–54.

Article  PubMed  Google Scholar 

Wells AU. High-resolution computed tomography and scleroderma lung disease. Rheumatology (Oxford). 2008;47(Suppl 5):v59-61.

Article  PubMed  Google Scholar 

Bailey DL, Maisey MN, Townsend DW, Valk PE. Positron emission tomography. London: Springer; 2005.

Volpi S, Ali JM, Tasker A, Peryt A, Aresu G, Coonar AS. The role of positron emission tomography in the diagnosis, staging and response assessment of non-small cell lung cancer. Ann Transl Med. 2018;6(5):95.

Article  PubMed  PubMed Central  Google Scholar 

Zerizer I, Tan K, Khan S, Barwick T, Marzola MC, Rubello D, Al-Nahhas A. Role of FDG-PET and PET/CT in the diagnosis and management of vasculitis. Eur J Radiol. 2010;73(3):504–9.

Article  PubMed  Google Scholar 

Jacquelin V, Mekinian A, Brillet PY, Nunes H, Fain O, Valeyre D, Soussan M. FDG-PET/CT in the prediction of pulmonary function improvement in nonspecific interstitial pneumonia. A Pilot Study Eur J Radiol. 2016;85(12):2200–5.

Article  CAS  PubMed  Google Scholar 

Uehara T, Takeno M, Hama M, Yoshimi R, Suda A, Ihata A, et al. Deep-inspiration breath-hold 18F-FDG-PET/CT is useful for assessment of connective tissue disease associated interstitial pneumonia. Mod Rheumatol. 2016;26(1):121–7.

Article  CAS  PubMed  Google Scholar 

Bellando-Randone S, Tartarelli L, Cavigli E, Tofani L, Bruni C, Lepri G, et al. 18F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis. Ann Rheum Dis. 2019;78(4):577–8.

Article  CAS  PubMed  Google Scholar 

Peelen DM, Zwezerijnen BGJC, Nossent EJ, Meijboom LJ, Hoekstra OS, Van der Laken CJ, Voskuyl AE. The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients. Rheumatology. 2020;59(6):1407–15.

Article  PubMed  Google Scholar 

Ledoult E, Morelle M, Soussan M, Mékinian A, Béhal H, Sobanski V, et al. (18)F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study. Arthritis Res Ther. 2021;23(1):76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spierings J, van Rhenen A, Welsing PMW, Marijnissen ACA, De Langhe E, Del Papa N, et al. A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. BMJ Open. 2021;11(3): e044483.

Article  PubMed  PubMed Central  Google Scholar 

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54.

Article  CAS  PubMed  Google Scholar 

Boellaard R. Quantitative oncology molecular analysis suite: ACCURATE. J Nucl Med. 2018;59(supplement 1):1753-.

Google Scholar 

Boktor RR, Walker G, Stacey R, Gledhill S, Pitman AG. Reference range for intrapatient variability in blood-pool and liver SUV for 18F-FDG PET. J Nucl Med. 2013;54(5):677–82.

Article  CAS  PubMed  Google Scholar 

Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18–47.

Article  PubMed  PubMed Central  Google Scholar 

Hoffmann-Vold A-M, Aaløkken TM, Lund MB, Garen T, Midtvedt Ø, Brunborg C, et al. Predictive Value of Serial High-Resolution Computed Tomography Analyses and Concurrent Lung Function Tests in Systemic Sclerosis. Arthritis & Rheumatology. 2015;67(8):2205–12.

Article  Google Scholar 

Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246(3):697–722.

Article  PubMed  Google Scholar 

Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology. 2012;52(1):155–60.

Article  PubMed  Google Scholar 

Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, et al. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. Arthritis Rheumatol. 2017;69(8):1670–8.

Article  CAS  PubMed  Google Scholar 

Panopoulos S, Bournia V-K, Konstantonis G, Fragiadaki K, Sfikakis PP, Tektonidou MG. Predictors of morbidity and mortality in early systemic sclerosis: Long-term follow-up data from a single-centre inception cohort. Autoimmun Rev. 2018;17(8):816–20.

Article  PubMed  Google Scholar 

Castiaux A, Van Simaeys G, Goldman S, Bondue B. Assessment of 18F-FDG uptake in idiopathic pulmonary fibrosis: influence of lung density changes. Eur J Hybrid Imaging. 2018;2(1):27.

Article  Google Scholar 

Motegi SI, Fujiwara C, Sekiguchi A, Hara K, Yamaguchi K, Maeno T, et al. Clinical value of (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis. J Dermatol. 2019;46(3):213–8.

Article  CAS  PubMed  Google Scholar 

Inoue K, Okada K, Taki Y, Goto R, Kinomura S, Fukuda H. (18)FDG uptake associated with CT density on PET/CT in lungs with and without chronic interstitial lung diseases. Ann Nucl Med. 2009;23(3):277–81.

Article  CAS  PubMed  Google Scholar 

Groves AM, Win T, Screaton NJ, Berovic M, Endozo R, Booth H, et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT. J Nucl Med. 2009;50(4):538–45.

Article